13F Insight
DOSSIER · 13F-HR · Q2 2026

Almitas Capital LLC

$417M in tracked AUM across 130 positions as of Q2 2026.

AC
CIK 0001596468 · last filed Jun 30, 2026
Total AUM
$417M
as of Q2 2026
Holdings
130
—
positions
Whale Score
58
58
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Almitas Capital LLC SEC 13F Filing
Portfolio Overview

Almitas Capital LLC has undergone a significant transformation in the quarter ending September 30, 2025. The firm executed a drastic reduction in portfolio size, with total assets under management (AUM) plummeting by 49.8%, falling from $396.36 million to $199.17 million. This reduction was accompanied by a substantial shift in strategy, evidenced by the disposal of 23 positions and the initiation ...

Key Holdings

The current portfolio composition reveals a "bar-bell" strategy, balancing high-yield fixed income and niche closed-end funds (CEFs) with high-risk, small-cap biotechnology equities.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
FBTC
FIDELITY WISE ORIGIN BITCOIN
$70M1.4M16.7%02
BTT
BLACKROCK MUN TARGET TERM TR
$34M1.5M8.1%03
G3156P103
ASA GOLD AND PRECIOUS MTLS L
$33M629K7.8%04
AMLX
AMYLYX PHARMACEUTICALS INC
$18M975K4.2%05
DSGN
DESIGN THERAPEUTICS INC
$15M1.0M3.6%06
PDX
PIMCO DYNAMIC INCOME STRATEG
$11M549K2.7%07
CRF
CORNERSTONE TOTAL RETURN FD
$11M1.6M2.7%08
CNNE
CANNAE HLDGS INC
$11M741K2.6%09
MEGI
NYLI CBRE GBL INFR MEGTRNDS
$8M557K2.0%10
LYEL
LYELL IMMUNOPHARMA INC
$8M581K2.0%

Filing history

2026Q2Jun 30
$417M▼ 5.7%
130 positionsView →2026Q1Mar 31
$443M▼ 2.6%
115 positionsView →2025Q4Dec 31
$454M▲ 5.7%
107 positionsView →2025Q3Sep 30
$430M▲ 8.4%
62 positionsView →2025Q2Jun 30
$396M▲ 31.5%
82 positionsLocked2025Q1Mar 31
$301M▼ 34.0%
81 positionsLocked2024Q4Dec 31
$456M▲ 61.3%
92 positionsLocked2024Q3Sep 30
$283M▲ 17.7%
69 positionsLocked2024Q2Jun 30
$241M▼ 0.6%
76 positionsLocked2024Q1Mar 31
$242M▼ 16.6%
69 positionsLocked2023Q4Dec 31
$290M▲ 39.0%
116 positionsLocked2023Q3Sep 30
$209M▼ 10.7%
88 positionsLocked
Showing 12 of 27